Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Michael E. Hurwitz, Sekwon Jang et al.|Journal of Clinical Oncology|2021Cited by 81
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 studyAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Regular and Young Investigator Award Abstracts|2020Cited by 7
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Regular and Young Investigator Award Abstracts|2020Cited by 3